PPD01.01 ctDNA Dynamics, Prognostic Markers and Resistance Mechanisms in Tepotinib-treated MET exon 14 (METex14) Skipping NSCLC in the VISION Trial
Xiuning Le(The University of Texas MD Anderson Cancer Center), Paul K. Paik(Memorial Sloan Kettering Cancer Center), Danyi Wang, Wade T. Iams(Vanderbilt University Medical Center), Christopher Stroh(Universität Hamburg), Myung‐Ju Ahn(Samsung Medical Center), Alexis B. Cortot(Centre National de la Recherche Scientifique), PierFranco Conte(University of Padua), Santiago Viteri(Instituto Oncológico Dr. Rosell), Hiroshi Sakai, Frank Griesinger(Carl von Ossietzky Universität Oldenburg), Dilafruz Juraeva(Merck KGaA, Darmstadt (Germany)), James Chih‐Hsin Yang(National Taiwan University Hospital), Julien Mazières(Université Toulouse III - Paul Sabatier), Enriqueta Felip(Institut Català d'Ornitologia), Marina Chiara Garassino(University of Chicago), Michael Thomas, R M O'Hara(Ono Pharmaceutical (United States)), Andreas Johne(Merck KGaA, Darmstadt (Germany))
Cited by 0
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k